A Clinical Stage Company

Developing small molecules targeting cancers, metabolic, neurodegenerative
and autoimmune diseases.

Our unique AI-enabled process designs innovative NCEs targeting any class of protein at unprecedented speed.


Target of Interest
  • Identify and validate structural proteins
  • Characterize target druggability through In Silico MolecuLern-driven workflow and experimental data
  • Real data tracking models
  • Hotspot residues
  • Validate binding pocket
  • AA property ennumeration
  • Iterative screening
  • Med-Chem tractability
  • Lead identification/selection
  • NCEs to synthesis
  • SAR to complete lead selection
  • ADME-Tox
  • Developability
  • Pre-formulation
  • Efficacy
  • Scale-up
NCE Molecule
Target Icon


Your training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions and discover targetable hot spots which minimizes the hit-and-miss nature of traditional drug discovery.

Target Icon


Cutting-edge platform based on decades of work, supported by over 5 years of AI/ML development that discovers new medicines with previously impossible speed and accuracy.


Target Icon


MolecuLern has been trained on hundreds of 3D structures, from both PDB and DeepMind AlphaFold protein targets, screened against our IP rich proprietary fragment and NCE library.

Proof of Concept

Proof of Concept - Updated Feb, 09, 2023

Contact Us

858 S Auto Mall Dr. #102
American Fork, UT 84003
United States

Ph: 801-692-3655   info@biolexistx.com